Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients

BACKGROUND: Anti‐PD1 checkpoint inhibitors (ICI) represent an established standard‐of‐care for patients with recurrent/metastatic head and neck squamous cell carcinoma (RMHNSCC). Landmark studies excluded patients with ECOG performance status (PS) ≥2; the benefit of ICI in this population is therefo...

Descripción completa

Detalles Bibliográficos
Autores principales: Chalker, Cameron, Voutsinas, Jenna M., Wu, Qian Vicky, Santana‐Davila, Rafael, Hwang, Victoria, Baik, Christina S., Lee, Sylvia, Barber, Brittany, Futran, Neal D., Houlton, Jeffrey J., Laramore, George E., Liao, Jay Justin, Parvathaneni, Upendra, Martins, Renato G., Eaton, Keith D., Rodriguez, Cristina P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678089/
https://www.ncbi.nlm.nih.gov/pubmed/35349227
http://dx.doi.org/10.1002/cam4.4722

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678089/
https://www.ncbi.nlm.nih.gov/pubmed/35349227
http://dx.doi.org/10.1002/cam4.4722

Ejemplares similares